

ASX Release

Anatara Lifesciences receives firm commitments for \$1.2m Placement

Highlights

- Firm commitments for Placement of 100 million shares at \$0.012 to raise \$1.2m (before costs) with existing and new institutional support
- Placement issue price of \$0.012 per new share represents a discount of 22.8% on the 15 day VWAP
- The funds will be used to further the Company's current Anti-Obesity project and due diligence on other opportunities and assets

ADELAIDE, 1 October 2025: Anatara Lifesciences (ASX: ANR) ("Anatara" or "the Company"), a developer of evidence-based solutions for unmet needs in human health, is pleased to announce that Anatara has received firm commitments for a two tranche placement to raise \$1,200,000 (before costs) through the proposed issue of 100,000,000 ordinary shares at \$0.012 per share (**Placement**) to new and existing sophisticated, professional and institutional investors.

The proceeds from the Placement will be utilised to fund the Company's Anti-Obesity Project (including an expectation to progress pre-clinical studies), for general working capital and costs associated with due diligence on other opportunities, as well as the Placement costs.

Executive Chair, David Brookes and newly appointed Non-Executive Director, Dirk van Dissel have committed to each subscribe for \$40,000 in the Placement, which will be subject to shareholder approval at Company's Annual General Meeting on 20 November 2025 (**AGM**).

Anatara's Chair, Dr. David Brookes, commented, "The Company appreciates the strong support from existing shareholders and welcomes those newer participants. Following the IBS trial results, the Company has been concentrating on liberating value from the GaRP project and progressing the Anti-Obesity program through to pre-clinical studies. The Company is now well capitalised and is intent on accelerating the evaluation of prospective opportunities and assets. As a Board, we are committed to returning value to our shareholders with exciting projects and encouraged by the institutional support to do so."

Placement

Anatara has received firm commitments to raise \$1.2 million at an issue price of \$0.012 per share through the proposed issue of 33,647,583 ordinary shares in tranche 1 and 66,352,417 ordinary shares in tranche 2 (subject to shareholder approval) (**Placement Shares**) to new and existing and professional, sophisticated and institutional investors.



The issue price of \$0.012 per Placement Share represents a discount of 27.8% to the 5 day VWAP price of Anatara shares on which trades were recorded immediately prior to launch of the Placement and a discount of approximately 22.8% to the 15 day VWAP. The Placement Shares will rank equally with existing fully paid ordinary shares in Anatara.

It is proposed that the issue of the first tranche of the Placement Shares will be issued under the Company's ASX Listing Rule 7.1 (13,788,550 shares) and 7.1A (19,859,033 shares) capacities and will occur on Wednesday 8 October 2025, subject to the receipt of funds on or before Tuesday, 7 October 2025. The second tranche of the Placement will be issued following shareholder approval at the Company's upcoming AGM.

Taylor Collison Limited was the sole Lead Manager and Bookrunner to the Placement. The Placement was not underwritten. Taylor Collison Limited will receive an overall management fee of 3% on \$1,120,000 of the Placement amount (representing gross proceeds excluding Director participation) and a 3% selling fee also applies to the Placement. Taylor Collison Limited will also receive 4,000,000 unlisted options (**Options**) that will have an exercise price of \$0.025 and an exercise period of 3 years from the date of their issue. The Options are being issued for financial services as part of the Placement. These Options will also be subject to shareholder approval at the Company's AGM.

This ASX announcement has been approved and authorised for release by the Board of Anatara.

For more information please contact:

Dr. David Brookes
Chair, Anatara Lifesciences Ltd
+61 (0) 411 712 579
dbrookes@anatara.com

About Anatara Lifesciences Ltd

Anatara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based health products where there is significant unmet need. Anatara is focused on building a pipeline of human health products with a particular focus on conditions that involve the complexity of the gastrointestinal tract. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.



Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation, and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

Anatara Lifesciences Limited
Registered Office
C/-PERKS Level 8,81 Flinders Street, Adelaide SA 5000
Email info@anatara.com | Website anataralifesciences.com



For personal use only